IPM Take
ADHD care has discovered adult women late. Pregnancy makes that failure harder to hide.
The new Ontario data show maternal ADHD diagnoses in pregnancy rising fourfold over two decades, while stimulant use before and during pregnancy also increased. That is not simply a prescribing trend. It is a care-pathway problem.
Women need guidance that treats ADHD as real during pregnancy, not as a diagnosis to be suspended until after delivery.
Executive Summary
A study published in The Journal of Clinical Psychiatry analysed all obstetrical deliveries in Ontario, Canada, from 2002 to 2023, with medication data available from 2014 onward.
Among 2,327,110 pregnancies, the proportion involving maternal ADHD rose from 0.5% in 2002 to 2.5% in 2023. Among pregnancies with maternal ADHD, stimulant medication use increased from 21.8% to 39.8% in the year before pregnancy and from 10.1% to 20.9% during pregnancy between 2014 and 2023.
Approximately 75% of those prescribed a stimulant in the year before conception discontinued it before or during the first trimester, with stable time trends.
The authors concluded that the rise in maternal ADHD and stimulant use underscores the need for clinical guidance on managing ADHD in pregnancy. The study describes trends; it does not determine the risks or benefits of stimulant continuation for individual mothers or infants.
Why it matters
- Patients / advocates: Pregnant women with ADHD need shared decision-making, not reflex discontinuation or unsupported continuation.
- Clinicians: The data point to a growing population where psychiatry, obstetrics and primary care need to coordinate better.
- Public authorities: Medication safety evidence and pregnancy guidance have not kept pace with changing diagnosis and prescribing patterns.
- Researchers / academia: The next need is not only prevalence data. It is outcome evidence that helps women make informed decisions.
Pregnancy often turns medical uncertainty into a woman’s private burden.
That is especially true in ADHD. A woman may be functioning at work, parenting, studying or managing a household because treatment helps her hold the day together. Then pregnancy arrives, and the question becomes suddenly more difficult: continue medication, stop it, reduce it, switch it or try to manage without support.
Too often, the system does not give a clear answer. It gives anxiety.
The Ontario study shows why this can no longer be treated as a marginal issue. Maternal ADHD diagnoses in pregnancy rose sharply between 2002 and 2023. Stimulant use before and during pregnancy also increased. At the same time, most women using stimulants before conception discontinued before or in the first trimester.
That pattern may reflect caution. It may reflect patient preference. It may reflect inadequate counselling. It may reflect a system that still treats women’s neuropsychiatric functioning as less important than theoretical risk.
The point is not that every pregnant woman with ADHD should remain on medication. The point is that every woman should have access to evidence, counselling and coordinated care before making a decision that can affect work, safety, emotional health and daily functioning.
ADHD does not pause because pregnancy begins.
A serious care pathway would not force women to make this decision in the dark.
